Cognitive Impairment clinical trials at UCSF
3 in progress, 0 open to eligible people
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
Sorry, currently not accepting new patients, but might later
The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline? Other questions this study aims to answer include: - Can researchers accurately assess THC consumption among frequent cannabis users? - Can researchers effectively incentivize cannabis users to use less potent THC products? - Do genetic variations in THC metabolism impact urinary THC excretion? - Do genetic variations in THC metabolism impact cognitive performance in cannabis users? - Are quantitative urinary THC values predictive of cognitive impairment? - How can researchers use research findings to inform harm reduction practices for people who use cannabis? Participants will submit blood and urine samples and be incentivized to use less potent THC products.
San Francisco, California
Music Improvisation Training on Cognitive Function in Older Adults
Sorry, in progress, not accepting new patients
This project will study the effects and mechanisms of a music improvisation training intervention on self-regulation of older adults with and without MCI. The investigator's overall hypothesis is that improvisation training will lead to improvements in self-regulation, compared to controls, and that improvisation training will be associated with specific changes in prefrontal brain networks and ultimately cognitive engagement.
San Francisco, California
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Sorry, in progress, not accepting new patients
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
San Francisco, California and other locations
Our lead scientists for Cognitive Impairment research studies include Alison Giovanelli Julene Johnson, PhD.
Last updated: